In vitro and in vivo cytogenetic effects of recombinant interleukin-2 on human lymphocytes.
To determine the cytogenetic effects of rIL-2, we investigated the rIL-2-induced sister chromatid exchange (SCE) and chromosomal aberrations in human peripheral lymphocytes in vitro and in patients given rIL-2 as a 24-hour infusion for 28 consecutive days. No significant increase in SCE frequency and chromosomal aberrations was observed after in vitro incubation of lymphocytes with 100 U/ml of rIL-2. A daily rIL-2 dose of 6.6 x 10(5) U/m2 did not induce any significant effect on SCE frequency and chromosomal aberrations while a marked increase was observed in the percentage of IL-2 receptor positive cells and HLA-DR positive cells. Although IL-2 therapy is only in developmental stage, our results suggest there is little or no potential mutagenic and/or carcinogenic hazard with this agent.
Shinkai
T
T
Division of Medical Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Tamura
T
T
Sano
T
T
Kojima
A
A
Eguchi
K
K
Sasaki
Y
Y
Ohe
Y
Y
Saijo
N
N
D000368:Aged; D002869:Chromosome Aberrations; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012854:Sister Chromatid Exchange / Q000187:drug effects
D007376:Interleukin-2; D011994:Recombinant Proteins